PE20181803A1 - Inhibidores de mcl-1 macrociclicos para tratar el cancer - Google Patents
Inhibidores de mcl-1 macrociclicos para tratar el cancerInfo
- Publication number
- PE20181803A1 PE20181803A1 PE2018001558A PE2018001558A PE20181803A1 PE 20181803 A1 PE20181803 A1 PE 20181803A1 PE 2018001558 A PE2018001558 A PE 2018001558A PE 2018001558 A PE2018001558 A PE 2018001558A PE 20181803 A1 PE20181803 A1 PE 20181803A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitors
- treat cancer
- mcl
- compounds
- refers
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 title abstract 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000032839 leukemia Diseases 0.000 abstract 1
- 210000000066 myeloid cell Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20181803A1 true PE20181803A1 (es) | 2018-11-19 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2018001558A PE20181803A1 (es) | 2016-04-22 | 2017-04-21 | Inhibidores de mcl-1 macrociclicos para tratar el cancer |
Country Status (38)
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3411046B1 (en) | 2016-02-04 | 2025-07-16 | The Johns Hopkins University | Rapaglutins, novel inhibitors of glut and use thereof |
| AU2017214557B2 (en) | 2016-02-04 | 2022-05-19 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| MX386103B (es) | 2016-04-22 | 2025-03-18 | Astrazeneca Ab | Inhibidores de mcl-1 y metodos de uso de los mismos. |
| US10981932B2 (en) | 2016-05-19 | 2021-04-20 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TWI781996B (zh) * | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| CN111818917A (zh) | 2017-08-15 | 2020-10-23 | 艾伯维公司 | 大环mcl-1抑制剂和使用方法 |
| US20200255451A1 (en) * | 2017-08-15 | 2020-08-13 | Abbvie Inc. | Macrocyclic mcl-1 inhibitors and methods of use |
| TWI810220B (zh) | 2017-11-17 | 2023-08-01 | 德商拜耳廠股份有限公司 | 經取代之巨環吲哚衍生物 |
| WO2019096909A1 (en) | 2017-11-17 | 2019-05-23 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| WO2019096914A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| WO2019096907A1 (en) * | 2017-11-17 | 2019-05-23 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| US11478451B1 (en) | 2017-11-17 | 2022-10-25 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| UY37973A (es) | 2017-11-17 | 2019-06-28 | Bayer Ag | Derivados de indol macrocíclicos |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| JP2022503896A (ja) * | 2018-09-30 | 2022-01-12 | ジエンス ヘンルイ メデイシンカンパニー リミテッド | インドール大環状誘導体、その調製方法、及びその医薬への応用 |
| TWI810397B (zh) | 2018-11-14 | 2023-08-01 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| US11691989B2 (en) | 2018-11-22 | 2023-07-04 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic indoles as Mcl-1 inhibitors |
| US12319703B2 (en) | 2019-01-23 | 2025-06-03 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrazoles as Mcl-1 inhibitors |
| KR20210153051A (ko) * | 2019-03-08 | 2021-12-16 | 제노 매니지먼트, 인크. | 매크로사이클릭 화합물 |
| CN113574058B (zh) * | 2019-04-30 | 2024-04-16 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| KR20220006613A (ko) | 2019-05-10 | 2022-01-17 | 얀센 바이오테크 인코포레이티드 | 마크로사이클릭 킬레이터 및 이의 사용 방법 |
| US12338250B2 (en) | 2019-05-17 | 2025-06-24 | The Broad Institute, Inc. | Methods of preparing macrocyclic indoles |
| CN114728076A (zh) | 2019-05-20 | 2022-07-08 | 诺华股份有限公司 | Mcl-1抑制剂抗体-药物缀合物及使用方法 |
| KR20220024694A (ko) * | 2019-06-21 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | Mcl-1의 거대환식 억제제 |
| WO2021005043A1 (en) | 2019-07-09 | 2021-01-14 | Janssen Pharmaceutica Nv | Macrocyclic spirocycle derivatives as mcl-1 inhibitors |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021099579A1 (en) | 2019-11-21 | 2021-05-27 | Janssen Pharmaceutica Nv | Macrocyclic indole derivatives as mcl-1 inhibitors |
| MX2022006180A (es) | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de sulfonilo como inhibidores de mcl-1. |
| CA3162963A1 (en) * | 2019-12-18 | 2021-06-24 | Zeno Management, Inc. | Macrocyclic compounds |
| JP2023514364A (ja) * | 2020-02-21 | 2023-04-05 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としての大環状インドール誘導体 |
| TW202144368A (zh) * | 2020-03-30 | 2021-12-01 | 大陸商江蘇恒瑞醫藥股份有限公司 | 吲哚類大環衍生物的結晶形式及其製備方法 |
| EP4157852A1 (en) | 2020-05-29 | 2023-04-05 | JANSSEN Pharmaceutica NV | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| MX2022015998A (es) * | 2020-06-19 | 2023-04-12 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1. |
| WO2021255257A1 (en) | 2020-06-19 | 2021-12-23 | Janssen Pharmaceutica Nv | N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| CA3184877A1 (en) | 2020-07-08 | 2022-01-13 | Benoit Christian Albert Ghislain De Boeck | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| KR20230138444A (ko) | 2020-11-24 | 2023-10-05 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| JP2023553719A (ja) | 2020-12-17 | 2023-12-25 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１阻害剤としての分岐大環状４－（ピラゾール－５－イル）－インドール誘導体 |
| JP2024506648A (ja) | 2021-02-12 | 2024-02-14 | ヤンセン ファーマシューティカ エヌ．ベー． | がんの治療のためのｍｃｌ－１阻害剤としての大環状１，３－架橋６－クロロ－７－ピラゾール－４－イル－１ｈ－インドール－２－カルボキシレート及び６－クロロ－７－ピリミジン－５－イル－１ｈ－インドール－２－カルボキシレート誘導体 |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| WO2022261301A1 (en) | 2021-06-11 | 2022-12-15 | Gilead Sciences, Inc. | Combination mcl-1 inhibitors with anti-cancer agents |
| CN115490708B (zh) * | 2021-06-18 | 2025-01-24 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| US20240401146A1 (en) | 2021-10-06 | 2024-12-05 | Institut National de la Santé et de la Recherche Médicale | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| KR20250027285A (ko) | 2022-05-20 | 2025-02-25 | 노파르티스 아게 | 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법 |
| WO2025111431A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd7 antibody-drug conjugates and methods of use thereof |
| WO2025111450A1 (en) | 2023-11-22 | 2025-05-30 | Les Laboratoires Servier | Anti-cd74 antibody-drug conjugates and methods of use thereof |
| TW202530255A (zh) | 2023-12-15 | 2025-08-01 | 法商亞維西亞有限公司 | 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8445679B2 (en) * | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| DK2134685T3 (en) | 2007-04-16 | 2015-12-07 | Abbvie Inc | 7-unsubstituted indole derivatives as MCL-1 inhibitors |
| PL2379580T3 (pl) * | 2008-12-22 | 2014-05-30 | Merck Sharp & Dohme | Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi |
| BR112012017756A2 (pt) * | 2009-12-23 | 2016-04-19 | Ironwood Pharmaceuticals Inc | moduladores crth2 |
| US9284334B2 (en) * | 2011-05-19 | 2016-03-15 | Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii | Macrocyclic compounds as protein kinase inhibitors |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| US10005728B2 (en) | 2013-08-28 | 2018-06-26 | Vanderbilt University | Substituted indole Mcl-1 inhibitors |
| US9944656B2 (en) * | 2014-02-12 | 2018-04-17 | VIIV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| WO2015148854A1 (en) | 2014-03-27 | 2015-10-01 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| CA2945237C (en) * | 2014-04-11 | 2022-09-06 | Ulrich Lucking | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| MX386103B (es) | 2016-04-22 | 2025-03-18 | Astrazeneca Ab | Inhibidores de mcl-1 y metodos de uso de los mismos. |
-
2017
- 2017-04-21 MX MX2018012711A patent/MX386103B/es unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en not_active Ceased
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es active IP Right Grant
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active Active
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-04-21 SM SM20200249T patent/SMT202000249T1/it unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181803A1 (es) | Inhibidores de mcl-1 macrociclicos para tratar el cancer | |
| AR123996A2 (es) | Compuestos tricíclicos novedosos como agentes antineoplásicos | |
| MX2023000410A (es) | Analogos de rapamicina como inhibidores de mtor. | |
| CO2019011762A2 (es) | Compuestos que inhiben la proteína mcl-1 | |
| MX2023010806A (es) | 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas. | |
| MX2021011209A (es) | Novedosos inhibidores de molécula pequeña de factores de transcripción tead. | |
| ES3041897T3 (en) | Compounds useful as kinase inhibitors | |
| CL2018002516A1 (es) | Inhibidores de mcl-1 indólicos sustituidos. | |
| EA201692114A1 (ru) | Замещенные дигидроизохинолиноновые соединения | |
| CO2018004964A2 (es) | Compuestos útiles como inmunomoduladores | |
| EA201690584A1 (ru) | Пестициды на основе замещенного гетероциклом бициклического азола | |
| CR20110059A (es) | Compuestos organicos | |
| MX2018007774A (es) | Compuestos heterociclicos como inmunomoduladores. | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| CL2017001336A1 (es) | Nuevos aminoácidos ester fosforamidatos 2' y/o 5', 3' deoxiadenosina derivativos como compuestos anticancerígenos | |
| MX374513B (es) | Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer. | |
| CU20150053A7 (es) | Inhibidores de bmi-1 de pirimidina inversa sustituida | |
| ECSP088536A (es) | DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR | |
| DOP2021000017A (es) | Compuestos de pirimidina y composiciones farmaceuticas para prevenir o tratar cánceres que incluyen los mismos | |
| PE20180231A1 (es) | Compuestos nucleosidos 5'-sustituidos | |
| CO2018005639A2 (es) | Sililfenoxiheterociclos trisustituidos y análogos | |
| MX2021002215A (es) | Derivados de tetrahidropiridopirimidina como moduladores de ahr. | |
| CL2019000538A1 (es) | Derivados de imidazol y su uso en tratamiento de enfermedades autoinmunes, inflamatorias o canceres. | |
| UY37225A (es) | Inhibidores del potenciador del homólogo zeste 2 campo de la invención |